W Q Gan1, S F P Man, A Senthilselvan, D D Sin. 1. The James Hogg iCAPTURE Center for Cardiovascular and Pulmonary Research, St Paul's Hospital, Room 368A, 1081 Burrard Street, Vancouver, British Columbia, Canada V6A 1Y6.
Abstract
BACKGROUND: Individuals with chronic obstructive pulmonary disease (COPD) are at increased risk of cardiovascular diseases, osteoporosis, and muscle wasting. Systemic inflammation may be involved in the pathogenesis of these disorders. A study was undertaken to determine whether systemic inflammation is present in stable COPD. METHODS: A systematic review was conducted of studies which reported on the relationship between COPD, forced expiratory volume in 1 second (FEV(1)) or forced vital capacity (FVC), and levels of various systemic inflammatory markers: C-reactive protein (CRP), fibrinogen, leucocytes, tumour necrosis factor-alpha (TNF-alpha), and interleukins 6 and 8. Where possible the results were pooled together to produce a summary estimate using a random or fixed effects model. RESULTS: Fourteen original studies were identified. Overall, the standardised mean difference in the CRP level between COPD and control subjects was 0.53 units (95% confidence interval (CI) 0.34 to 0.72). The standardised mean difference in the fibrinogen level was 0.47 units (95% CI 0.29 to 0.65). Circulating leucocytes were also higher in COPD than in control subjects (standardised mean difference 0.44 units (95% CI 0.20 to 0.67)), as were serum TNF-alpha levels (standardised mean difference 0.59 units (95% CI 0.29 to 0.89)). CONCLUSIONS: Reduced lung function is associated with increased levels of systemic inflammatory markers which may have important pathophysiological and therapeutic implications for subjects with stable COPD.
BACKGROUND: Individuals with chronic obstructive pulmonary disease (COPD) are at increased risk of cardiovascular diseases, osteoporosis, and muscle wasting. Systemic inflammation may be involved in the pathogenesis of these disorders. A study was undertaken to determine whether systemic inflammation is present in stable COPD. METHODS: A systematic review was conducted of studies which reported on the relationship between COPD, forced expiratory volume in 1 second (FEV(1)) or forced vital capacity (FVC), and levels of various systemic inflammatory markers: C-reactive protein (CRP), fibrinogen, leucocytes, tumour necrosis factor-alpha (TNF-alpha), and interleukins 6 and 8. Where possible the results were pooled together to produce a summary estimate using a random or fixed effects model. RESULTS: Fourteen original studies were identified. Overall, the standardised mean difference in the CRP level between COPD and control subjects was 0.53 units (95% confidence interval (CI) 0.34 to 0.72). The standardised mean difference in the fibrinogen level was 0.47 units (95% CI 0.29 to 0.65). Circulating leucocytes were also higher in COPD than in control subjects (standardised mean difference 0.44 units (95% CI 0.20 to 0.67)), as were serum TNF-alpha levels (standardised mean difference 0.59 units (95% CI 0.29 to 0.89)). CONCLUSIONS: Reduced lung function is associated with increased levels of systemic inflammatory markers which may have important pathophysiological and therapeutic implications for subjects with stable COPD.
Authors: Juanita H Vernooy; Mehmet Küçükaycan; Jan A Jacobs; Niels H Chavannes; Wim A Buurman; Mieke A Dentener; Emiel F Wouters Journal: Am J Respir Crit Care Med Date: 2002-11-01 Impact factor: 21.405
Authors: A A Eid; A A Ionescu; L S Nixon; V Lewis-Jenkins; S B Matthews; T L Griffiths; D J Shale Journal: Am J Respir Crit Care Med Date: 2001-10-15 Impact factor: 21.405
Authors: Aruna D Pradhan; JoAnn E Manson; Jacques E Rossouw; David S Siscovick; Charles P Mouton; Nader Rifai; Robert B Wallace; Rebecca D Jackson; Mary B Pettinger; Paul M Ridker Journal: JAMA Date: 2002-08-28 Impact factor: 56.272
Authors: Timothy W Shipley; Heather M Kling; Alison Morris; Sangita Patil; Jan Kristoff; Siobhan E Guyach; Jessica E Murphy; Xiuping Shao; Frank C Sciurba; Robert M Rogers; Thomas Richards; Paul Thompson; Ronald C Montelaro; Harvey O Coxson; James C Hogg; Karen A Norris Journal: J Infect Dis Date: 2010-07-15 Impact factor: 5.226
Authors: Roy T M Sprooten; Kaatje Lenaerts; Dionne C W Braeken; Ilvy Grimbergen; Erica P Rutten; Emiel F M Wouters; Gernot G U Rohde Journal: Respiration Date: 2018-01-25 Impact factor: 3.580
Authors: Diana C Grootendorst; Stefanie A Gauw; Renate M Verhoosel; Peter J Sterk; Jeannette J Hospers; Dirk Bredenbröker; Thomas D Bethke; Pieter S Hiemstra; Klaus F Rabe Journal: Thorax Date: 2007-06-15 Impact factor: 9.139